CorrectChemo is the only test on the market to help oncologists find the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient.
Nashville, Tennessee (PRWEB) May 12, 2015
DiaTech Oncology, provider of CorrectChemo®, the industry leading functional drug response profiling test that personalizes cancer treatment, has signed a partnership with INETICO, a leading claims and care management solutions company for insurance providers and employee groups, to offer the Correct Chemo™ test through the “My Custom Chemo” cancer management protocol to INETICO and DiaTech clients.
“CorrectChemo is the only test on the market to help oncologists find the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient. As our clinical studies show, the test can guide therapy in individual patients, leading to longer survival times and lower costs,” says Dr. Cary Presant, chief medical officer for DiaTech.
Prior to treatment, CorrectChemo provides the oncologist with a unique data set, revealing which chemotherapy agent, or combination of agents, are most likely to kill the cancer cells of a specific patient.
Inetico will offer CorrectChemo through INETICARE, the Care Management division of INETICO as “My Custom Chemo,” providing the most proactive and comprehensive suite of services available in the marketplace today.
“We have been able to offer many programs and solutions that allow improved care and claims savings at a time when rising costs are a challenge,” says Joseph Hodges, INETICO founder and chief executive officer. “This represents the first time we have been able to offer a test as part of our cancer management solution that may dramatically improve outcomes for cancer patients. CorrectChemo helps oncologists find the right chemo treatment the first time. It’s a valuable diagnostic tool to help shorten the treatment duration and its side effects as well as control escalating costs of chemotherapy agents. That’s a benefit to health plans, providers and patients.”
About DiaTech Oncology
DiaTech Oncology, based in Nashville, Tenn., is a privately held life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. Now called CorrectChemo, the test evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective. It is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. DiaTech has CLIA and CAP certified laboratories in Franklin, Tennessee and Montreal, Quebec, Canada.
INETICO provides health care cost containment services to self-funded, fully insured, and travel plan members through plan document writing, clearinghouse, data normalization, PPO network administration, referenced base rates, care management, electronic claims management, out-of-network negotiations and subrogation. INETICARE, a division of INETICO, provides solutions and care management programs that include a team of Registered Nurses, URAC-accredited Physician Advisors, and a Board-Certified Medical Director. INETICARE’s care management suite of services advocates wellness, prevention of uncontrolled disease states through condition management, and healthcare intervention with access to a highly-skilled continuum of healthcare provider partners. The Tampa-based company, founded in 2004, has been a rising member of the Inc. 5000 list of America’s fastest-growing private companies since 2011.